Regulation of VEGF expression by PPAR in human lung cancer cells

Research Project

Project/Area Number	20790562
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Respiratory organ internal medicine
Research Institution	Asahikawa Medical College
Principal Investigator	TANNO Sachie Asahikawa Medical College, 大学病院, 医員 (80455724)
Project Period (FY)	2008 – 2009
Project Status	Completed (Fiscal Year 2009)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords	チアゾリジン誘導体 / 肺がん / collagen XVIII / PPARgamma / 血管新生抑制因子 / PPAR / VEGF / VEGFR / 肺癌 / AKT
Research Abstract	Thiazolidinedione (TZD) use in patients with diabetes was specifically associated with reduced risk of lung cancer. Since collagen XVIII is one of the strongest predictors of outcome in patients with lung cancer, we examined the effects of TZD on expression of collagen XVIII in human non-small lung cancer (NSCLC) cells. The present results results suggest for the first time that TZDs reduced expression of collagen XVIII in NSCLC, which may help us understand the mechanism why TZDs use has chemopreventive action.